Saphenous vein thrombophlebitis (SVT): A deceptively benign disease

Abstract

The incidence of the hypercoagulable state in patients with SVT is high. Thirty-five percent of patients with isolated SVT had consistently abnormal coagulation profiles. Patients with SVT may be prone to the development of DVT or saphenofemoral junction thrombophlebitis and should be closely followed after the initial diagnosis of hypercoagulability.

Clinical Features and Developing Risks of Saphenous Vein Thrombophlebitis

“…1) Malignancy was also reported to have a weak association with superficial thrombophlebitis. 1) Patients with superficial thrombophlebitis should be screened for hypercoagulability because of their high prevalence of hypercoagulable states caused by a deficiency in antithrombin III or abnormalities in protein C and S. 1,13) Male gender, history of thromboembolism, severe venous insufficiency, and shorter interval between symptom onset and diagnosis (less than 7 days) are also reported to be risk factors associated with complications after superficial vein thrombosis. 12) In this study, Protein C deficiency, hormone therapy, malignancy, and driving as an occupation were found to increase the risk of thrombosis.…”

Prevalence of Isolated Asymptomatic Deep Vein Thrombosis in Varicose Vein Patients with Superficial Thrombophlebitis: A Single Center Experience in Japan

“…On the other hand, Hanson et al reported that, among patients with saphenous vein thrombosis and DVT, 35% of those had abnormal coagulation profiles, 13) suggesting that examination of coagulation profiles is necessary in varicose vein patients with STP.…”

Superficial Vein Thrombosis

“…The incidence of thrombophilia is also increased in patients with SVT [ 10,13,[15][16][17] . It may be useful to evaluate patients with SVT who do not have varicose veins and have one other risk factor for SVT for markers of thrombophilia including protein S de fi ciency, protein C de fi ciency, anticardiolipin antibodies, beta2 glycoprotein, factor V Leiden, prothrombin mutation, antithrombin de fi ciency, lupus anticoagulant, methylene tetrahydrofolate reductase de fi ciency, and fasting serum homocysteine [ 10,13,16,[18][19][20] .…”

“…All patients received enoxaparin (0.1 mL/10 kg) and elastic compression for treatment period Hanson (1998) [ 15 ] Open (N = 17) Anticoagulation is mandatory in patients with SVT when DVT is present. Anticoagulation is also often used when a thrombus is found in the SPJ or SFJ or extends as free fl oating in the CFV or popliteal veins.…”